MX2023008249A - Forma de dosificacion en tableta solida de ridinilazol. - Google Patents

Forma de dosificacion en tableta solida de ridinilazol.

Info

Publication number
MX2023008249A
MX2023008249A MX2023008249A MX2023008249A MX2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A
Authority
MX
Mexico
Prior art keywords
ridinilazole
solid tablet
benzimidazole
pyridin
dosage form
Prior art date
Application number
MX2023008249A
Other languages
English (en)
Inventor
Peter Timmins
Jean-Francois Carniaux
Francis X Wilson
Laura Trespidi
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of MX2023008249A publication Critical patent/MX2023008249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas de dosificación oral en tabletas sólidas de 2,2'-di(piridin-4-il)-1H,1'H-5,5'-bibenzo[d]im idazol (que también se puede conocer como 2,2'-di-4-piridinil-6,6' -bi-1H-bencimidazol; 5,5'-bis[2-(4-piridinil)-1H-bencimidazol]; 2,2'-bis(4-piridil)-3H,3'H-5,5'-bibencimidazol; o 2-piridin-4-il-6-(2-piridin-4-il-3H-bencimidazol-5-il)-1H-bencimi dazol), al que se hace referencia en la presente descripción con el nombre INN ridinilazol y derivados, sales, hidratos, solvatos, complejos, bioisósteros, metabolitos o profármacos farmacéuticamente aceptables del mismo.
MX2023008249A 2021-01-14 2022-01-14 Forma de dosificacion en tableta solida de ridinilazol. MX2023008249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2100470.0A GB202100470D0 (en) 2021-01-14 2021-01-14 Solid tablet dosage for of ridinilazole
PCT/IB2022/050311 WO2022153246A1 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Publications (1)

Publication Number Publication Date
MX2023008249A true MX2023008249A (es) 2023-07-26

Family

ID=74679044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008249A MX2023008249A (es) 2021-01-14 2022-01-14 Forma de dosificacion en tableta solida de ridinilazol.

Country Status (11)

Country Link
US (1) US20220226249A1 (es)
EP (1) EP4277604A1 (es)
JP (1) JP2024503689A (es)
KR (1) KR20230131253A (es)
CN (1) CN116801867A (es)
AU (1) AU2022207756A1 (es)
CA (1) CA3145677A1 (es)
GB (1) GB202100470D0 (es)
IL (1) IL304354A (es)
MX (1) MX2023008249A (es)
WO (1) WO2022153246A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds

Also Published As

Publication number Publication date
JP2024503689A (ja) 2024-01-26
WO2022153246A1 (en) 2022-07-21
AU2022207756A9 (en) 2024-05-09
KR20230131253A (ko) 2023-09-12
CN116801867A (zh) 2023-09-22
IL304354A (en) 2023-09-01
EP4277604A1 (en) 2023-11-22
AU2022207756A1 (en) 2023-07-27
GB202100470D0 (en) 2021-03-03
US20220226249A1 (en) 2022-07-21
CA3145677A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
CR20220258A (es) Inhibidores de kras g12c
CR20230066A (es) Agonistas del glp-1 heterocíclicos
TN2020000158A1 (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
TW200640900A (en) 1-(2h)-isoquinolone derivative
MX2022009524A (es) Agonistas heterociclicos de glp-1.
CR20210608A (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
UA90763C2 (ru) Производные пиразола, способ их получения, фармацевтический состав на их основе и их применение
WO2006107860A3 (en) Dihydropyridine compounds and compositions for headaches
JP2016536363A5 (es)
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
MY141024A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
RS54904B1 (sr) Antibakterijske farmaceutske kompozicije
SI1487444T1 (sl) Uporaba piridil-amidov kot inhibitorjev angiogeneze
WO2006057922A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
MX2021009763A (es) Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
MX2022013657A (es) Quimioterápicos de éter macrocíclico heteroaromático.
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
CY1124643T1 (el) Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης
MX2023008249A (es) Forma de dosificacion en tableta solida de ridinilazol.
NO20080033L (no) Kinolinderivater som NK3-antagonister
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
PL1858861T3 (pl) Hamujące HIV 2-(4-cyjanofenylo)-6-hydroksyloaminopirymidyny